Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulcrum Therapeutics (FULC) Treasury Shares (2018 - 2026)

Fulcrum Therapeutics (FULC) has 9 years of Treasury Shares data on record, last reported at $90.1 million in Q1 2026.

  • On a quarterly basis, Treasury Shares rose 102222.6% to $90.1 million in Q1 2026 year-over-year; TTM through Mar 2026 was $90.1 million, a 102222.6% increase, with the full-year FY2025 number at $69.5 million, up 161225.22% from a year prior.
  • Treasury Shares reached $90.1 million in Q1 2026 per FULC's latest filing, up from $69.5 million in the prior quarter.
  • Over the last five years, Treasury Shares for FULC hit a ceiling of $90.1 million in Q1 2026 and a floor of $43072.0 in Q4 2024.
  • A 5-year average of $20.0 million and a median of $88048.0 in 2025 define the central range for Treasury Shares.
  • Peak YoY movement for Treasury Shares: plummeted 42.58% in 2024, then surged 161225.22% in 2025.
  • Tracing FULC's Treasury Shares over 5 years: stood at $76718.0 in 2022, then decreased by 2.22% to $75017.0 in 2023, then tumbled by 42.58% to $43072.0 in 2024, then soared by 161225.22% to $69.5 million in 2025, then rose by 29.66% to $90.1 million in 2026.
  • Business Quant data shows Treasury Shares for FULC at $90.1 million in Q1 2026, $69.5 million in Q4 2025, and $69.5 million in Q3 2025.